Dallas, Texas (July 27, 2011) – StockGuru shines its Spotlight on PediatRx, Inc. (“PediatRx”) (OTCBB: PEDX), a hospital specialty company with a current focus on oncology supportive care. Yesterday the Company provided an update on activities for the fiscal first quarter ended May 31, 2011. Major accomplishments in the first quarter include the continued establishment of relationships with wholesalers, distributors and group purchasing organizations and the addition of GRANISOL® to the U.S. Centers for Medicare/Medicaid list of reimbursable products. The Company closed on July 26, 2011, at $0.85; its fifty-two week range is $1.29 – 0.51.
“We are excited to have made such significant progress this quarter in establishing new relationships and infrastructure that are critical to growing future sales,” said Dr. Cameron Durrant, the founder of PediatRx. “We expect our focused strategy to market and sell GRANISOL through multiple channels and to key oncology hospitals and clinics to result in a strong and exciting year for PediatRx.”
PediatRx’s most notable achievements to date include:
- Net product revenue of approximately $103,020 for the fiscal first quarter ended May 31, 2011 and $369,828 since launching the product in November, 2010. No revenue had been recognized by the company prior to 2010.
- Gross margin of approximately $86,288 on first quarter product sales and $267,533 since launching the product in November, 2010.
- Continued initiation of sales and marketing initiatives to support GRANISOL sales.
- Deployment of three sales representatives to promote the product in the field directly to healthcare professionals.
- Successful launch of GRANI Cares (http://www.121hm.com/offers/granisol), a co-pay program to support use of GRANISOL.
- Establishment of agreements with key wholesalers, distributors and group purchasing organizations to support the commercialization and future growth of GRANISOL.
- Approval by the Center for Medicare and Medicaid Services to include PediatRx’s GRANISOL on the list of reimbursed products for Medicaid and the Section 340B Drug Pricing Program.
- $250,000 in debt financing for the first quarter and a total of $2.08 million in equity financings and a total of $450,000 in debt financing since June, 2010.
Key objectives for the remainder of 2011 include:
- Continued focus on growing product revenues.
- Aggressively market the merits of GRANISOL to healthcare professionals, payers, end users and their caregivers.
- Explore ex-US partnerships for GRANISOL.
- Actively pursue additional product acquisitions.
- Actively pursue corporate development transactions.
A summary of key financial highlights for the three months and fiscal year ended February 28, 2011 is as follows ($thousands):
| As of and for the three month period ended May 31, 2011 |
As of and for the three month period ended May 31, 2011 |
|
| Net revenues | $ 103.0 | $ – |
| Gross margin | 86.3 | – |
| Operating expenses | 537.5 | 16.5 |
| Net loss for the period | (451.2) | (16.5) |
| Cash and cash equivalents | 448.7 | 2.1 |
| Current assets | 607.7 | 2.1 |
| Current liabilities | 577.8 | 65.5 |
| Working capital | 29.9 | (63.4) |
A complete set of unaudited financial statement is available in the Company’s Quarterly Report on Form 10-Q for the quarter ended May 31, 2011, which is available on the Securities and Exchange Commission’s EDGAR database at www.SEC.Gov.
Used for the prevention of nausea and vomiting associated with initial and repeat courses of chemotherapy or radiation, GRANISOL is the only FDA-approved granisetron available as a ready-to-use oral liquid solution.
Selected Safety Information
- GRANISOL is contraindicated in patients with known hypersensitivity to the drug or any of its components.
- QT prolongation has been reported with granisetron. Therefore, GRANISOL Oral Solution should be used in caution with patients with pre-existing arrhythmias or cardiac conduction disorders, as this might lead to clinical consequences. Patients with cardiac disease, on cardio-toxic chemotherapy, with concomitant electrolyte abnormalities and/or on concomitant medications that prolong the QT interval are particularly at risk.
- Safety and effectiveness in pediatric patients have not been established.
- The most common side effects observed with administration of granisetron were headache, asthenia, constipation, diarrhea, dyspepsia, and abdominal pain.
About PediatRx
PediatRx, Inc. (www.pediatrx.com) is a hospital specialty pharmaceutical company which focuses on treatments for patients suffering from serious conditions requiring hospitalization. PediatRx trades on the OTCBB under the ticker symbol PEDX.
This press release contains forward-looking statements. Forward-looking statements are projections of events, revenues, income, future economics, research, development, reformulation, product performance or management’s plans and objectives for future operations. In some cases you can identify forward-looking statements by the use of terminology such as “may”, “should”, “anticipates”, “believes”, “expects”, “intends”, “forecasts”, “plans”, “future”, “strategy”, or words of similar meaning. Forward-looking statements in this press release include those concerning PediatRx’s expectation that its focused strategy will result in a strong and exciting year and its key objectives for the remainder of 2011 include continued focus on growing product revenues, aggressive marketing of the merits of GRANISOL to healthcare professionals, payers, end users and their caregivers, exploration of ex-U.S. partnerships, the active pursuit of additional product acquisitions and the active pursuit of corporate development transactions. While these forward-looking statements and any assumptions upon which they are based are made in good faith and reflect current judgment regarding the direction of the business operations of PediatRx, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested in this press release. These statements are predictions and involve known and unknown risks, uncertainties and other factors, including the risk that PediatRx cannot execute its business plan for lack of capital or other resources, distribution, partnering or licensing/acquisition opportunities, as well as the risks described in the periodic disclosure documents filed on EDGAR by PediatRx, copies of which are also available on the company’s website. Any of these risks could cause PediatRx or its industry’s actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by the forward-looking statements in this press release. Except as required by applicable law, including the securities laws of the United States, PediatRx does not intend to update any of the forward-looking statements to conform these statements to actual results.
To view this StockGuru Spotlight, please visit: http://stockguru.com/category/latest-spotlights/
To get free alerts on this and other similar stocks, please register here:
What is the StockGuru Spotlight?
Many companies covered in The StockGuru Spotlight have positive increases in both volume and share price. While this is not true in all cases, StockGuru strives to cover companies in The StockGuru Spotlight that are worth of our readers’ attention.
StockGuru looks for potential break-out candidates in The StockGuru Spotlight. Many of these companies have had recent news and appear to be getting the attention of investors. StockGuru does not typically feature companies in The StockGuru Spotlight that are compensating StockGuru for this coverage. There are times when StockGuru covers a stock in The StockGuru Spotlight that had previously compensated Stockguru. Where that is the case, a proper disclosure is included below. StockGuru and its partners, employees and writers never hold shares, short positions, warrants or any other current position in a stock featured in The StockGuru Spotlight.
To feature a company in The StockGuru Spotlight please contact the Publisher at [email protected]. If our reader is a key person for a publicly traded company, StockGuru can consider that company for either a StockGuru Spotlight or a StockGuru Profile. Please contact the StockGuru Publisher John Pentony at this email address: [email protected].
Stockguru.com (“SG”) provides its members with the latest news, press releases, and trade alerts for all the companies highlighted on the site StockGuru.com. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.Stockguru.com or mentioned herein.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements. StockGuru is occasionally compensated for coverage. When this is the case, SG clearly indicates this with a disclosure of all compensation received in the past and present. Additionally SG also discloses any anticipated compensation in the future. Compensation is typically in cash. Sometimes a company pays SG in restricted shares. Pentony Enterprise and its associated companies does not take free trading shares for any reason at anytime. StockGuru is not a registered investment adviser or a broker-dealer. StockGuru makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.
John Pentony, Publisher, Stockguru.com
Tel: +1 469 252 3031
e-mail: [email protected]